Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus Option

Open Ended Schemes(Equity Scheme - Sectoral/ Thematic)Very High RiskISIN INF204K01I27

NAV · 06-Jul-2026

₹634.5567

+6.46%

+10.62%

1Y (CAGR)

+9.51%

3Y (CAGR)

+22.47%

5Y (CAGR)

+13.74%

Since inception (CAGR)

+17.70%

NAV history

hover for values

Risk & SIP analytics

Q1 · TOP · 3Y in category

Volatility (3y)

13.03%

Downside dev (3y)

9.10%

Max drawdown (3y)

-14.7%

Sharpe (3y)

1.23

SIP XIRR (3y)

+14.88%

SIP XIRR (5y)

+18.27%

Calendar-year returns

2020 +67.9%2021 +25.1%2022 -9.1%2023 +40.4%2024 +35.3%2025 -2.5%

Fund facts

Fund managerSailesh Raj Bhan · Kinjal Desai · Amber Singhania

AUM₹86,357 Cr

Expense ratio0.79% · 2026-05-31

TER · AMFI officialDirect 1.02% · Regular 1.86% (2026-06-30)

Launch date10-May-2004

Plan typeOpen Ended · Equity

Min lumpsum₹5,000

Min SIP₹0

Lock-inNone

Volatility15.44

AMCNippon Life India Asset Management Limited

Objective · The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

scheme documents ↗